FDA approves NeuroMetrix pain device

The FDA grants 510(k) clearance to NeuroMetrix's (NURO) Sensus chronic pain treatment device. The wearable product delivers non-invasive electrical stimulation to sensory nerves as a method to relieve pain. It can be worn day and night and will be available over-the-counter without a prescription.

NURO shares are up 28% premarket on light volume.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs